Q: Who should receive the shingles vaccine?

Cleve Clin J Med. 2009 Jan;76(1):45-8. doi: 10.3949/ccjm.75a.08046.
No abstract available

MeSH terms

  • Aged
  • Cost-Benefit Analysis
  • Herpes Zoster / immunology
  • Herpes Zoster / prevention & control*
  • Herpes Zoster Vaccine / adverse effects
  • Herpes Zoster Vaccine / economics
  • Herpes Zoster Vaccine / immunology*
  • Herpesvirus 3, Human / immunology*
  • Humans
  • United States
  • Vaccination

Substances

  • Herpes Zoster Vaccine